Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Treatment of lung infection in patients with cystic fibrosis: current and future strategies

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Defining antimicrobial resistance in cystic fibrosis

    Research output: Contribution to journalReviewResearchpeer-review

  2. The choice of lung function reference equation affects clinical trial eligibility: Results from a cystic fibrosis cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. IgG avidity to Pseudomonas aeruginosa over the course of chronic lung biofilm infection in cystic fibrosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Mechanisms of humoral immune response against Pseudomonas aeruginosa biofilm infection in cystic fibrosis

    Research output: Contribution to journalReviewResearchpeer-review

  5. Prevalence and characteristics of chronic kidney disease among Danish adults with cystic fibrosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The importance of early diagnosis of Mycobacterium abscessus complex in patients with cystic fibrosis

    Research output: Contribution to journalReviewResearchpeer-review

  2. Next generation microbiology and cystic fibrosis diagnostics: are we there yet?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The accessibility of topical treatment in the paranasal sinuses on operated cystic fibrosis patients assessed by scintigraphy

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Gerd Döring
  • Patrick Flume
  • Harry Heijerman
  • J Stuart Elborn
  • Consensus Study Group
  • Niels Høiby
View graph of relations
In patients with cystic fibrosis (CF) lung damage secondary to chronic infection is the main cause of death. Treatment of lung disease to reduce the impact of infection, inflammation and subsequent lung injury is therefore of major importance. Here we discuss the present status of antibiotic therapy for the major pathogens in CF airways, including prophylaxis against infection, eradication of early infection, suppression of chronic infection, and the treatment of infective exacerbations. We outline measures to optimize maintenance treatment for infection in the light of novel antibiotic drug formulations. We discuss new developments in culture-independent microbiological diagnostic techniques and the use of tools for monitoring the success of antibiotic treatment courses. Finally, cost-effectiveness analyses for antibiotic treatment in CF patients are discussed.
Original languageEnglish
JournalJournal of Cystic Fibrosis
Volume11
Issue number6
Pages (from-to)461-79
Number of pages19
ISSN1569-1993
DOIs
Publication statusPublished - 2012

ID: 36806003